Can't find what you're looking for?
View all search resultsCan't find what you're looking for?
View all search resultshe European Commission has ordered 30,000 treatment doses of the antiviral medication remdesivir from US drugs giant Gilead, it announced Wednesday.
Sold under the brand name Veklury, remdesivir is the first medicine to be approved by the EU to treat victims of the COVID-19 pandemic in EU member states and Britain.
It is hoped the drug will shorten recovery times for patients with severe infections and it will be made available early next month.
The first batch of doses will cost 63 million euros ($73 million) and ought to cover needs for the next few months before a second procurement contract in October.
Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.
Thank you for sharing your thoughts. We appreciate your feedback.
Quickly share this news with your network—keep everyone informed with just a single click!
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
Get the best experience—faster access, exclusive features, and a seamless way to stay updated.